<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161483</url>
  </required_header>
  <id_info>
    <org_study_id>CC-220-SLE-002</org_study_id>
    <secondary_id>U1111-1195-7804</secondary_id>
    <nct_id>NCT03161483</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2, multicenter, randomized, placebo-controlled, double-blind study&#xD;
      to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in&#xD;
      adult subjects with active systemic lupus erythematosus.&#xD;
&#xD;
      Approximately 280 subjects with a documented diagnosis of SLE will be randomized 2:2:1:2 to&#xD;
      receive CC-220 (0.45 mg QD, 0.3 mg QD or 0.15 mg QD) or identically appearing placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of four phases:&#xD;
&#xD;
        -  4-week Screening Phase&#xD;
&#xD;
        -  24-week placebo-controlled phase Subjects will receive either 0.45 mg QD, 0.3 mg QD,&#xD;
           0.15 mg QD or placebo for the first 24 weeks of treatment.&#xD;
&#xD;
        -  28-week active treatment phase At Week 24, all subjects on placebo will be re-randomized&#xD;
           to active treatment.&#xD;
&#xD;
        -  52-week long-term extension phase Subjects who complete the treatment phase may be&#xD;
           eligible to roll over into a Long-term Extension of up to 52 weeks of treatment.&#xD;
&#xD;
        -  4 - 12-week observational follow-up All subjects who complete 52 weeks of treatment or&#xD;
           discontinue the study early will enter a post-treatment observation follow-up phase. The&#xD;
           Observational Follow-up Phase will consist of one visit 4 weeks following cessation of&#xD;
           study drug for all subjects with an additional 12-week Observational Follow-up visit for&#xD;
           males only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response</measure>
    <time_frame>Week 24</time_frame>
    <description>The primary objective is to evaluate the clinical efficacy of three doses of CC-220 (0.45 mg once per day [QD], 0.3 mg QD or 0.15 mg QD) compared to placebo, for the treatment of active systemic lupus erythematosus (SLE) using the SLE Responder Index at Week 24&#xD;
Composite endpoint SRI(4), defined by the following criteria:&#xD;
Reduction from Baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and&#xD;
No new one or more British Isles Lupus Assessment Group (BILAG) A or new (excludes A to B) 2 or more BILAG B items compared to Baseline using BILAG 2004 Index and&#xD;
No worsening from Baseline defined by an increase of &lt; 0.30 points from Baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With SLEDAI 2K Score Improvement of ≥ 4 Points From Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>The SLEDAI 2K score measures disease activity through assessment of 24 lupus manifestations using a weighted score of 1 to 8 points. A manifestation is recorded if it is present over the previous 30 days regardless of severity or whether it has improved or worsened. A SLEDAI 2K score of 3 to 4 points is representative of active disease and a decrease of 1 to 2 points is considered clinically meaningful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a ≥ 50% Reduction in Cutaneous Lupus Area and Severity Index (CLASI) Activity Score From Baseline, in Participants With Baseline CLASI Activity Score ≥ 10</measure>
    <time_frame>Week 24</time_frame>
    <description>The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and non-scarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no New Organ System Affected as Defined by 1 or More BILAG A or New (Excludes A to B) 2 or More BILAG B Items Compared to Baseline Using BILAG 2004 Index</measure>
    <time_frame>Week 24</time_frame>
    <description>The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Worsening (Increase of &lt; 0.30 Points From Baseline) in PGA Compared to Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Swollen Joint Count in Participants With ≥ 2 Swollen Joints at Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.&#xD;
Note: Data presented is Adjusted mean data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Tender Joint Count in Participants With ≥ 2 Tender Joints at Baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.&#xD;
Note: Data presented is Adjusted mean data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PGA Score</measure>
    <time_frame>Week 24</time_frame>
    <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score</measure>
    <time_frame>Week 24</time_frame>
    <description>The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means &quot;not at all,&quot; and 4 means &quot;very much.&quot; The total FACIT-Fatigue score ranges from 0 to 52.&#xD;
Note: Data presented is Adjusted mean data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Corticosteroid Reduction</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24&#xD;
The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to &lt; 10 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Corticosteroid Reduction</measure>
    <time_frame>Week 24</time_frame>
    <description>Percent change from Baseline in oral corticosteroid (OCS) dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline&#xD;
Note: Data presented is Adjusted mean data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Corticosteroid Dose From Baseline Through Week 24</measure>
    <time_frame>Through Week 24</time_frame>
    <description>Standardized total oral corticosteroid (OCS) dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>from first dose to 28 days post-last dose through Week 24 (placebo-controlled phase), approximately 28 weeks total</time_frame>
    <description>Number of participants who experienced a TEAE during the course of the study</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>CC-220 0.45 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)&#xD;
At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)&#xD;
Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-220 0.3 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)&#xD;
At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)&#xD;
Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC-220 0.15 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)&#xD;
At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)&#xD;
Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-220</intervention_name>
    <description>CC-220</description>
    <arm_group_label>C-220 0.3 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>CC-220 0.15 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>CC-220 0.45 mg QD Placebo Controlled Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD PO</description>
    <arm_group_label>C-220 0.3 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>CC-220 0.15 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>CC-220 0.45 mg QD Placebo Controlled Phase</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 years of age or older at the time of signing the informed consent.&#xD;
&#xD;
          -  Have a diagnosis of SLE for at least 6 months prior to the Screening Visit and fulfill&#xD;
             the 1997 update of the 1982 American College of Rheumatology (ACR) Classification&#xD;
             Criteria for SLE at the Screening Visit.&#xD;
&#xD;
          -  A SLEDAI 2K score of ≥ 6 points, WITH at least 4 points being a &quot;clinical&quot; SLEDAI 2K&#xD;
             score. The &quot;clinical&quot; score excludes points attributable to any urine or blood&#xD;
             laboratory results including immunologic measures.&#xD;
&#xD;
          -  At the Baseline Visit, a clinical SLEDAI 2K score of ≥ 4 points.&#xD;
&#xD;
          -  Have at least one of the following positive antibodies associated with SLE per the&#xD;
             central laboratory within the Screening Phase:&#xD;
&#xD;
               -  Positive antinuclear antibody (ANA) test at the central laboratory with a titer&#xD;
                  of 1:40 or greater, associated with a diagnosis of SLE,&#xD;
&#xD;
               -  Anti-dsDNA antibodies elevated to above normal&#xD;
&#xD;
               -  Anti-Smith (anti-Sm) antibody elevated to above normal&#xD;
&#xD;
          -  Females of childbearing potential must: Have two negative pregnancy tests as verified&#xD;
             by the Investigator prior to starting study therapy. She must agree to ongoing&#xD;
             pregnancy testing during the course of the study, and after end of study treatment.&#xD;
&#xD;
             o Either commit to true abstinence from heterosexual contact or agree to use two forms&#xD;
             of reliable contraception simultaneously.&#xD;
&#xD;
          -  Male subjects must: Practice true abstinence or agree to use a barrier contraception&#xD;
             during sexual contact.&#xD;
&#xD;
        All subjects must:&#xD;
&#xD;
          -  Understand that the IP could have potential teratogenic risk.&#xD;
&#xD;
          -  Agree to abstain from donating blood while taking IP and for 28 days following&#xD;
             discontinuation of the IP.&#xD;
&#xD;
               -  Have been treated with at least one of the following SLE medications prior to the&#xD;
                  Screening Visit: antimalarials, immunosuppressants, and/or corticosteroids.&#xD;
&#xD;
               -  Currently receiving stable doses of at least one of the following medications:&#xD;
                  systemic corticosteroids, antimalarials, and/or immunosuppressants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received intra-articular, intralesional, subcutaneous, intradermal, intramuscular or&#xD;
             IV pulse corticosteroids 6 weeks prior to the Baseline Visit.&#xD;
&#xD;
          -  Received any other biologic or non-biologic immunosuppressive agent within 2 months of&#xD;
             5 pharmacokinetic half-lives (whichever is longer) prior to the Baseline Visit.&#xD;
&#xD;
          -  Have severe lupus nephritis defined as: estimated glomerular filtration rate of &lt; 45&#xD;
             mL/1.73 m2 or proteinuria &gt; 2000 mg/day based on protein to creatinine ratio, or&#xD;
             active lupus nephritis that may require 'induction' therapy&#xD;
&#xD;
          -  Have active, severe or unstable neuropsychiatric lupus disease within 6 months of the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  Have serologic tests consistent with infection with either hepatitis B or hepatitis C,&#xD;
             and/or confirmed history of hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Have history of congenital and/or acquired immunodeficiencies (eg, common variable&#xD;
             immunodeficiency, human immunodeficiency virus, etc).&#xD;
&#xD;
          -  Have active or history of recurrent bacterial, viral, fungal, mycobacterial or other&#xD;
             infections, or any major episode of infection requiring hospitalization or treatment&#xD;
             with intravenous or oral antibiotics within 4 weeks of the Screening Visit and at any&#xD;
             time during the Screening Phase, up through the first dose of IP.&#xD;
&#xD;
          -  Have active tuberculosis or a history of latent or active tuberculosis&#xD;
&#xD;
          -  Have malignancy or history of malignancy, except for:&#xD;
&#xD;
               -  treated (eg, cured) basal cell or squamous cell in situ skin carcinomas&#xD;
&#xD;
               -  treated (eg, cured) cervical intraepithelial neoplasia Grade 1 and Grade 2&#xD;
&#xD;
               -  treated (eg, cured) carcinoma in situ of the cervix with no evidence of&#xD;
                  recurrence within 5 years of the Screening Visit.&#xD;
&#xD;
          -  Have a diagnosis or history consistent with Antiphospholipid Syndrome or &quot;triple&#xD;
             antiphospholipid positivity&quot; (ie, positive lupus anticoagulant, anticardiolipin, and&#xD;
             anti-B2 glycoprotein).&#xD;
&#xD;
          -  Have history of arterial or venous thrombosis&#xD;
&#xD;
          -  Have history or current diagnosis of peripheral neuropathy (sensory or motor) ≥ Grade&#xD;
             2.&#xD;
&#xD;
          -  Have presence of active uveitis or any other ophthalmological finding that in the&#xD;
             opinion of the Investigator is clinically significant.&#xD;
&#xD;
          -  Have other non-SLE driven inflammatory joint or skin disease or overlap syndromes as&#xD;
             the primary disease.&#xD;
&#xD;
          -  Have clinically significant or unstable or uncontrolled acute or chronic disease not&#xD;
             due to SLE&#xD;
&#xD;
          -  Does not meet required laboratory criteria.&#xD;
&#xD;
          -  Does not meet pre-specified periods for prohibited medications.&#xD;
&#xD;
          -  Pregnant or a breast-feeding female.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nataliya Agafonova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center of Alabama, PC</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Rsch, PLLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Heritage Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C Michael Neuwelt M D</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre For Rheumatology, Immun. And Arthritis</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology and Immunology Specialists</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Care Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital - Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefrey Lieberman, MD, PC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033-5910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Robert Hozman</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland - School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Center of Rheumatology</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Associates of New Mexico</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011-4741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System-Division of Rheumatology</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanahan Rheumatology and Immunotherapy</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Systems</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony's Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-8807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Department of Dermatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh UPMC Lupus Center of Excellence</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology &amp; Arthritis Research Center, PC</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organización Médica de Investigación</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Jose Maria Ramos Mejia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultora Integral de Salud Centro Médico Privado</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro Medico de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CER Instituto Mèdico</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas de Quilmes</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Internacional de Pesquisas</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Terapias Inovadoras LTDA</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Servicos Medicos S/S</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of Campinas UNICAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre, RS</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Imunoterapia de Ipanema (CITIPA)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22411-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3Y1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Research Incorporated</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUL du CHU de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Rhumatologie Du Centre Du Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Centro Integral de Reumatologia del Caribe Circaribe S.A.S.</name>
      <address>
        <city>Barranquilla</city>
        <zip>080002</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S. - Cireem S.A.S</name>
      <address>
        <city>Bogota</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idearg S.A.S.</name>
      <address>
        <city>Bogota</city>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servimed S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preventive Care</name>
      <address>
        <city>Chia</city>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumalab - Centro Integral de Reumatologia</name>
      <address>
        <city>Medellin</city>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille France</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique - Hopitaux de Paris - Hopital Universitaire Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic kft</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili P.O. di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ferrara, Azienda Ospedaliera-Universitaria S.Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Cagliari</name>
      <address>
        <city>Monserrato</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Artritis y Osteoporosis</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <zip>21200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biológicos Especializados S.A. de C.V.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Integral de Osteoporosis y Artitis Reumatoide CLINOSAR</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación y Tratamiento Reumatológico</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral en Reumatología, S.A. de C.V.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación del Potosí S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis Potosí</state>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Atencion Medica e Investigacion en Salud, S.C.</name>
      <address>
        <city>Merida</city>
        <state>Yucatán</state>
        <zip>97130</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles Lindavista</name>
      <address>
        <city>D.f, Df</city>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zespól Opieki Zdrowotnej w Koscianie Szpital im. Teodora Dunina</name>
      <address>
        <city>Koscian</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Reumatologii i Ukladowych Chorob Tkanki Laczne</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Biogenes Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital</name>
      <address>
        <city>Kazan</city>
        <zip>420103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kemerovo State Medical Academy</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences Research Institute of Rheumatology of the Ru</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg State Medical Academy</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg Research Institute for Emergency Medical Care</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leningrad Regional Clinical Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Higher Educational Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioMed, LLC.</name>
      <address>
        <city>Vladimir</city>
        <zip>600005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Voronezh Regional Clinical Hopsital #1, Voronezh State Medical Academy</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology Belgrade</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Niska Banja</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario a Coruna</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba - Txagorritxu</name>
      <address>
        <city>Vitoria-Gasteiz</city>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nakayama Y, Kosek J, Capone L, Hur EM, Schafer PH, Ringheim GE. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. J Immunol. 2017 Oct 1;199(7):2388-2407. doi: 10.4049/jimmunol.1601725. Epub 2017 Aug 28.</citation>
    <PMID>28848067</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <results_first_submitted>January 19, 2021</results_first_submitted>
  <results_first_submitted_qc>February 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-220</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Active Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03161483/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03161483/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Placebo-controlled phase: 289 participants were randomized and 288 treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PBO QD</title>
          <description>Placebo-matching treatment once a day</description>
        </group>
        <group group_id="P2">
          <title>0.15 mg QD</title>
          <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
        </group>
        <group group_id="P3">
          <title>0.30 mg QD</title>
          <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
        </group>
        <group group_id="P4">
          <title>0.45 mg QD</title>
          <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PBO QD</title>
          <description>Placebo-matching treatment once a day</description>
        </group>
        <group group_id="B2">
          <title>0.15 mg QD</title>
          <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
        </group>
        <group group_id="B3">
          <title>0.30 mg QD</title>
          <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
        </group>
        <group group_id="B4">
          <title>0.45 mg QD</title>
          <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="81"/>
            <count group_id="B5" value="288"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="13.3"/>
                    <measurement group_id="B2" value="43.8" spread="13.0"/>
                    <measurement group_id="B3" value="44.7" spread="13.7"/>
                    <measurement group_id="B4" value="46.4" spread="11.2"/>
                    <measurement group_id="B5" value="44.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 40 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 40 to &lt;= 50</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 50 to &lt; 65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 65</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="278"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not collected or reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response</title>
        <description>The primary objective is to evaluate the clinical efficacy of three doses of CC-220 (0.45 mg once per day [QD], 0.3 mg QD or 0.15 mg QD) compared to placebo, for the treatment of active systemic lupus erythematosus (SLE) using the SLE Responder Index at Week 24&#xD;
Composite endpoint SRI(4), defined by the following criteria:&#xD;
Reduction from Baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and&#xD;
No new one or more British Isles Lupus Assessment Group (BILAG) A or new (excludes A to B) 2 or more BILAG B items compared to Baseline using BILAG 2004 Index and&#xD;
No worsening from Baseline defined by an increase of &lt; 0.30 points from Baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3</description>
        <time_frame>Week 24</time_frame>
        <population>Primary analysis based on Intent-to-treat (ITT) Population (all randomized participants who received at least one dose of investigational product) and nonresponder imputation (NRI). Participants with insufficient data for response determination at the given time point are considered nonresponders.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieve SLE Responder Index (SRI) (4) Response</title>
          <description>The primary objective is to evaluate the clinical efficacy of three doses of CC-220 (0.45 mg once per day [QD], 0.3 mg QD or 0.15 mg QD) compared to placebo, for the treatment of active systemic lupus erythematosus (SLE) using the SLE Responder Index at Week 24&#xD;
Composite endpoint SRI(4), defined by the following criteria:&#xD;
Reduction from Baseline of ≥ 4 points in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2K score and&#xD;
No new one or more British Isles Lupus Assessment Group (BILAG) A or new (excludes A to B) 2 or more BILAG B items compared to Baseline using BILAG 2004 Index and&#xD;
No worsening from Baseline defined by an increase of &lt; 0.30 points from Baseline on a Physician's Global Assessment (PGA) visual analog scale (VAS) from 0-3</description>
          <population>Primary analysis based on Intent-to-treat (ITT) Population (all randomized participants who received at least one dose of investigational product) and nonresponder imputation (NRI). Participants with insufficient data for response determination at the given time point are considered nonresponders.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.214</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.57</ci_lower_limit>
            <ci_upper_limit>29.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.77</ci_lower_limit>
            <ci_upper_limit>19.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>19.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.12</ci_lower_limit>
            <ci_upper_limit>33.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With SLEDAI 2K Score Improvement of ≥ 4 Points From Baseline</title>
        <description>The SLEDAI 2K score measures disease activity through assessment of 24 lupus manifestations using a weighted score of 1 to 8 points. A manifestation is recorded if it is present over the previous 30 days regardless of severity or whether it has improved or worsened. A SLEDAI 2K score of 3 to 4 points is representative of active disease and a decrease of 1 to 2 points is considered clinically meaningful.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT population. Participants with insufficient data for response determination at the given time point are considered nonresponders.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SLEDAI 2K Score Improvement of ≥ 4 Points From Baseline</title>
          <description>The SLEDAI 2K score measures disease activity through assessment of 24 lupus manifestations using a weighted score of 1 to 8 points. A manifestation is recorded if it is present over the previous 30 days regardless of severity or whether it has improved or worsened. A SLEDAI 2K score of 3 to 4 points is representative of active disease and a decrease of 1 to 2 points is considered clinically meaningful.</description>
          <population>ITT population. Participants with insufficient data for response determination at the given time point are considered nonresponders.</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.66</ci_lower_limit>
            <ci_upper_limit>27.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.45</ci_lower_limit>
            <ci_upper_limit>21.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>19.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.01</ci_lower_limit>
            <ci_upper_limit>33.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a ≥ 50% Reduction in Cutaneous Lupus Area and Severity Index (CLASI) Activity Score From Baseline, in Participants With Baseline CLASI Activity Score ≥ 10</title>
        <description>The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and non-scarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT population with Baseline CLASI activity score ≥ 10</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a ≥ 50% Reduction in Cutaneous Lupus Area and Severity Index (CLASI) Activity Score From Baseline, in Participants With Baseline CLASI Activity Score ≥ 10</title>
          <description>The CLASI Activity Score ranges from 0 to 70. To generate the activity score erythema is scored on a scale of 0 (absent) to 3 (dark red; purple/violaceous/crusted/hemorrhagic) and scale/hypertrophy are scored on a scale of 0 (absent) to 2 (verrucous/hypertrophic). Both the erythema and scale/hypertrophy scores are assessed in 13 different anatomical locations. In addition, the presence of mucous membrane lesions is scored on a scale of 0 (absent) to 1 (lesion or ulceration), the occurrence of recent hair loss is captured (1=yes; 0=no) and non-scarring alopecia is scored on a scale of 0 (absent) to 3 (focal or patchy in more than one quadrant). To calculate the activity score, all scores for erythema, scale/hypertrophy, mucous membrane lesions and alopecia are added together.</description>
          <population>ITT population with Baseline CLASI activity score ≥ 10</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.446</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>24.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.38</ci_lower_limit>
            <ci_upper_limit>53.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.64</ci_lower_limit>
            <ci_upper_limit>39.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>14.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.54</ci_lower_limit>
            <ci_upper_limit>44.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no New Organ System Affected as Defined by 1 or More BILAG A or New (Excludes A to B) 2 or More BILAG B Items Compared to Baseline Using BILAG 2004 Index</title>
        <description>The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity.</description>
        <time_frame>Week 24</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no New Organ System Affected as Defined by 1 or More BILAG A or New (Excludes A to B) 2 or More BILAG B Items Compared to Baseline Using BILAG 2004 Index</title>
          <description>The BILAG 2004 is a composite index that is based on the Classic BILAG index. It is a clinical measure of lupus disease activity. This tool assesses the changing severity of clinical manifestations of SLE using an ordinal scale scoring system that contain 9 systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and hematological). Activity in each organ system is scored as: A=most active disease; B=intermediate activity; C=mild, stable disease; D=previous involvement, currently inactive; E=no previous activity.</description>
          <population>All treated participants</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.74</ci_lower_limit>
            <ci_upper_limit>24.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.434</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.43</ci_lower_limit>
            <ci_upper_limit>8.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.182</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.88</ci_lower_limit>
            <ci_upper_limit>19.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Worsening (Increase of &lt; 0.30 Points From Baseline) in PGA Compared to Baseline</title>
        <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
        <time_frame>Week 24</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Worsening (Increase of &lt; 0.30 Points From Baseline) in PGA Compared to Baseline</title>
          <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
          <population>All treated participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="90.5"/>
                    <measurement group_id="O3" value="73.2"/>
                    <measurement group_id="O4" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.098</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.98</ci_lower_limit>
            <ci_upper_limit>23.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.521</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.36</ci_lower_limit>
            <ci_upper_limit>8.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Stratified difference</param_type>
            <param_value>6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.24</ci_lower_limit>
            <ci_upper_limit>18.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Swollen Joint Count in Participants With ≥ 2 Swollen Joints at Baseline</title>
        <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.&#xD;
Note: Data presented is Adjusted mean data.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population; Subjects with &gt;=2 Swollen Joints, with a baseline value and a value at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Swollen Joint Count in Participants With ≥ 2 Swollen Joints at Baseline</title>
          <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.&#xD;
Note: Data presented is Adjusted mean data.</description>
          <population>ITT Population; Subjects with &gt;=2 Swollen Joints, with a baseline value and a value at the time point.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" lower_limit="-7.2" upper_limit="-6.2"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-6.7" upper_limit="-5.3"/>
                    <measurement group_id="O3" value="-6.0" lower_limit="-6.7" upper_limit="-5.2"/>
                    <measurement group_id="O4" value="-6.6" lower_limit="-7.1" upper_limit="-6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.094</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.881</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Tender Joint Count in Participants With ≥ 2 Tender Joints at Baseline</title>
        <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.&#xD;
Note: Data presented is Adjusted mean data.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population; Participants with &gt;=2 Tender Joints, with a baseline value and a value at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Tender Joint Count in Participants With ≥ 2 Tender Joints at Baseline</title>
          <description>Joint tenderness and swelling will be noted as &quot;present&quot; or &quot;absent,&quot; with no quantitation of severity using a 28- joint count.&#xD;
Note: Data presented is Adjusted mean data.</description>
          <population>ITT Population; Participants with &gt;=2 Tender Joints, with a baseline value and a value at the time point.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" lower_limit="-8.8" upper_limit="-7.0"/>
                    <measurement group_id="O2" value="-6.8" lower_limit="-8.1" upper_limit="-5.6"/>
                    <measurement group_id="O3" value="-6.7" lower_limit="-7.7" upper_limit="-5.6"/>
                    <measurement group_id="O4" value="-7.6" lower_limit="-8.5" upper_limit="-6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.160</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PGA Score</title>
        <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT population with a baseline value and a value at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PGA Score</title>
          <description>The PGA uses a visual analog scale with scores between 0 and 3 to indicate worsening of disease. The scoring is as follows: 0 = none, 1 = mild disease, 2 = moderate disease, and 3 = severe disease.</description>
          <population>ITT population with a baseline value and a value at the time point.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.803" spread="0.605"/>
                    <measurement group_id="O2" value="-0.805" spread="0.528"/>
                    <measurement group_id="O3" value="-0.819" spread="0.629"/>
                    <measurement group_id="O4" value="-0.883" spread="0.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score</title>
        <description>The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means &quot;not at all,&quot; and 4 means &quot;very much.&quot; The total FACIT-Fatigue score ranges from 0 to 52.&#xD;
Note: Data presented is Adjusted mean data.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT population; participants with a baseline value and a value at the time point</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score</title>
          <description>The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means &quot;not at all,&quot; and 4 means &quot;very much.&quot; The total FACIT-Fatigue score ranges from 0 to 52.&#xD;
Note: Data presented is Adjusted mean data.</description>
          <population>ITT population; participants with a baseline value and a value at the time point</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.6" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.7" lower_limit="-0.3" upper_limit="5.6"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.9" upper_limit="5.4"/>
                    <measurement group_id="O4" value="5.2" lower_limit="3.0" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.546</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.681</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.350</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted mean</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Corticosteroid Reduction</title>
        <description>The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24&#xD;
The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to &lt; 10 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population; Participants with Baseline OCS Dose &gt;= 10 mg/day&#xD;
Participants with insufficient data for response determination at the given time point are considered nonresponders.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Corticosteroid Reduction</title>
          <description>The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to ≤ 7.5 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24&#xD;
The percentage of participants with a prednisone or equivalent dose of ≥ 10 mg/day at Baseline whose prednisone or equivalent dose has been reduced to &lt; 10 mg/day by Week 16 and maintained through Week 24 with no flares between Week 16 and Week 24</description>
          <population>ITT Population; Participants with Baseline OCS Dose &gt;= 10 mg/day&#xD;
Participants with insufficient data for response determination at the given time point are considered nonresponders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, &lt;= 7.5 mg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, &lt; 10 mg/day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>&lt;= 7.5 mg/day</non_inferiority_desc>
            <p_value>&gt;0.999</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Stratified difference</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.13</ci_lower_limit>
            <ci_upper_limit>15.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>&lt; 10 mg/day</non_inferiority_desc>
            <p_value>&gt;0.999</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Stratified difference</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.74</ci_lower_limit>
            <ci_upper_limit>13.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Corticosteroid Reduction</title>
        <description>Percent change from Baseline in oral corticosteroid (OCS) dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline&#xD;
Note: Data presented is Adjusted mean data.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT Population; Participants with the Baseline OCS Dose &gt;= 10 mg/day, with a baseline value and a value at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Corticosteroid Reduction</title>
          <description>Percent change from Baseline in oral corticosteroid (OCS) dose in subjects with prednisone or equivalent ≥ 10 mg/day at Baseline&#xD;
Note: Data presented is Adjusted mean data.</description>
          <population>ITT Population; Participants with the Baseline OCS Dose &gt;= 10 mg/day, with a baseline value and a value at the time point.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" lower_limit="-13.6" upper_limit="-2.2"/>
                    <measurement group_id="O2" value="-5.1" lower_limit="-11.9" upper_limit="1.6"/>
                    <measurement group_id="O3" value="-3.8" lower_limit="-9.5" upper_limit="2.0"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-6.4" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.535</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted means</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.309</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted means</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>longitudinal data analysis model</method>
            <param_type>Difference in adjusted means</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Corticosteroid Dose From Baseline Through Week 24</title>
        <description>Standardized total oral corticosteroid (OCS) dose.</description>
        <time_frame>Through Week 24</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Corticosteroid Dose From Baseline Through Week 24</title>
          <description>Standardized total oral corticosteroid (OCS) dose.</description>
          <population>ITT population</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1139.7" spread="916.9"/>
                    <measurement group_id="O2" value="1101.9" spread="827.1"/>
                    <measurement group_id="O3" value="1071.8" spread="965.0"/>
                    <measurement group_id="O4" value="1105.5" spread="969.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>Number of participants who experienced a TEAE during the course of the study</description>
        <time_frame>from first dose to 28 days post-last dose through Week 24 (placebo-controlled phase), approximately 28 weeks total</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD</title>
            <description>Placebo-matching treatment once a day</description>
          </group>
          <group group_id="O2">
            <title>0.15 mg QD</title>
            <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
          </group>
          <group group_id="O3">
            <title>0.30 mg QD</title>
            <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
          </group>
          <group group_id="O4">
            <title>0.45 mg QD</title>
            <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>Number of participants who experienced a TEAE during the course of the study</description>
          <population>All treated participants</population>
          <units>Number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Drug Interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Drug Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 28 days post-last dose of the placebo-controlled phase (through Week 24), approximately 28 weeks total.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PBO Controlled - PBO</title>
          <description>Placebo-matching treatment once a day</description>
        </group>
        <group group_id="E2">
          <title>PBO Controlled - 0.15 mg QD</title>
          <description>Participants dosed with CC-220 at 0.15 mg once a day</description>
        </group>
        <group group_id="E3">
          <title>PBO Controlled - 0.30 mg QD</title>
          <description>Participants dosed with CC-220 at 0.30 mg once a day</description>
        </group>
        <group group_id="E4">
          <title>PBO Controlled - 0.45 mg QD</title>
          <description>Participants dosed with CC-220 at 0.45 mg once a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email:</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

